Reimbursed Care Access in Paraguay

Currently classified as a strictly controlled substance under Paraguay's national drug control framework with no authorized medical use or reimbursement outside of approved research. The national drug authority (SENAD) maintains and enforces an updated list of controlled psychoactive substances under Decree N° 5282/2021 and Law N° 1.340/1988; possession, distribution or commercialization of psilocybin-containing products is subject to criminal penalties and enforcement actions. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. SENAD has publicly reported seizures and enforcement actions involving MDMA (ecstasy) and lists synthetic empathogens among controlled substances; there is no public reimbursement pathway for MDMA‑assisted therapy in Paraguay. # #

There is no public record of regulatory approval, national reimbursement, or routine clinical availability of esketamine (Spravato) as a marketed, reimbursed product in Paraguay. Paraguay’s drug‑registration and sanitary surveillance authorities (DINAVISA / Ministry of Health) and SENAD regulate imports and the national list of controlled medicines; I could not identify an official marketing authorization or listing for esketamine in Paraguayan registries or public Ministry pages. Therefore, access would be limited to formal clinical research protocols or special import authorizations (compassionate use) where permitted by DINAVISA and overseen by institutional review boards — but no national reimbursement framework for esketamine is evident. # #

Ketamine is an approved medicinal anesthetic and analgesic in Paraguay, distributed as injectable formulations and used routinely in hospital and veterinary practice; marketed ketamine products are listed in Paraguayan pharmacopeia/vademécum resources, and the substance is subject to controlled‑substance regulation rather than a blanket prohibition. #

Off‑label psychiatric use: there are emerging, institutionally supervised programs and clinical services using ketamine infusions for severe/refractory psychiatric conditions (for example, programs described at academic clinical centers such as the Hospital de Clínicas program reported in local sources). These initiatives operate under hospital/clinic medical practice rules and local ethics/regulatory oversight and are not universally reimbursed by public insurance; access is typically private or project‑based and may require out‑of‑pocket payment or institutional funding. #

Regulatory context: despite medical availability, ketamine is listed among controlled psychoactive substances and is subject to SENAD/DINAVISA oversight — diversion and illicit trafficking are enforcement priorities (numerous press reports document seizures). Reimbursement for ketamine when used as an anesthetic follows standard medication procurement channels in public hospitals, but psychiatric (off‑label) indications lack an established, reimbursed national pathway. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Paraguayan authorities have acted against commercial ayahuasca/ DMT offerings (e.g., recent SENAD/DINAVISA coordinated interventions seizing ayahuasca preparations sold as 'sanctuary' services), indicating active enforcement and lack of a legal medical or religious exemption framework. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No public regulatory framework or reimbursement pathway exists in Paraguay for 5‑MeO‑DMT. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of an approved medical program, licensing or reimbursement for ibogaine treatment in Paraguay; international sources underscore that ibogaine commonly exists in legal gray zones in many countries, but Paraguay treats novel psychoactive substances under SENAD controls. # #

Currently classified under controlled‑substance regulation (DMT is controlled) and there is no authorized medical or broadly recognized religious exemption for public ceremonies; commercial sale and distribution of ayahuasca preparations have been subject to enforcement actions by SENAD/DINAVISA (recent raid and seizures), demonstrating that organized ceremonial/commercial use is not legally protected and carries criminal risk. There is no reimbursement pathway for ayahuasca-based therapy. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Traditional cactus preparations containing mescaline have no recognized medical reimbursement pathway or legal religious exemption in Paraguay. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Synthetic phenethylamines (2C family) are included within Paraguay's updated lists or fall under analogous controlled‑substance provisions and are targeted by enforcement. # #